Barrington analyst Alexander Paris lowered the firm’s price target on HealthEquity (HQY) to $112 from $120 and keeps an Outperform rating on the shares. The company recently reported Q3 results that topped expectations and raised its fiscal 2025 guidance, the analyst tells investors in a research note. However, the initial fiscal 2026 guidance was mixed, with revenue slightly below consensus expectations but adjusted EBITDA margins slightly ahead of consensus expectations, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HQY:
- HealthEquity price target raised to $105 from $100 at RBC Capital
- HealthEquity price target raised to $107 from $105 at JMP Securities
- HealthEquity, Inc. Shows Strong Q3 Financial Growth
- Closing Bell Movers: Oracle slips 8% after Q2 earnings miss, disappointing guide
- HealthEquity sees FY26 revenue $ $1.275B-1.295B, consensus $1.32B